Ryaltris Nasal Spray Approved for Seasonal Allergic Rhinitis

The Food and Drug Administration (FDA) has approved Ryaltris (olopatadine hydrochloride, mometasone furoate) nasal spray for the treatment of symptoms associated with seasonal allergic rhinitis in adults and pediatric patients 12 years of age and older.

Ryaltris is a metered, fixed-dose, prescription nasal spray that delivers 665mcg of olopatadine hydrochloride, an antihistamine, and 25mcg of mometasone furoate, a corticosteroid, in each spray. The approval was based on data from 2 randomized, double-blind, placebo- and active-controlled phase 3 studies (ClinicalTrials.gov Identifier: [Study 1] NCT02631551, [Study 2] NCT02870205) that evaluated the efficacy and safety of Ryaltris in a total of 2352 patients 12 years of age and older with seasonal allergic rhinitis.

Patients were randomly assigned to receive 1 of 4 treatments: Ryaltris, olopatadine hydrochloride nasal spray, mometasone furoate nasal spray, or placebo for 2 weeks. The primary endpoint for both studies was the change from baseline in average morning and evening patient-reported 12-hour reflective total nasal symptom score (rTNSS) over the 14-day treatment period.

Continue Reading

Findings showed that treatment with Ryaltris resulted in statistically significant improvement in rTNSS compared with olopatadine hydrochloride, mometasone furoate, and placebo. However, a statistically significant difference was not observed when Ryaltris was compared with mometasone furoate in Study 1.

Both studies met key secondary endpoints demonstrating statistically significant improvement in the average morning and evening patient-reported 12-hour instantaneous total nasal symptom score and the reflective total ocular symptom score compared with placebo. The most common adverse reactions reported with Ryaltris were dysgeusia, epistaxis, and nasal discomfort.

Ryaltris is supplied in a bottle containing 240 metered sprays in addition to 6 initial priming sprays. The product will be marketed and distributed through Hikma Specialty USA Inc.


  1. Glenmark Specialty SA (Switzerland) receives NDA approval by the United States Food and Drug Administration (FDA) for Ryaltris™ nasal spray for the treatment of symptoms of seasonal allergic rhinitis in adults and pediatric patients 12 years of age and older. News release. Glenmark Pharmaceuticals Limited. Accessed January 14, 2022. https://www.prnewswire.com/news-releases/glenmark-specialty-sa-switzerland-receives-nda-approval-by-the-united-states-food-and-drug-administration-fda-for-ryaltris-nasal-spray-for-the-treatment-of-symptoms-of-seasonal-allergic-rhinitis-in-adults-and-pediatric-pati-301461096.html 
  2. Ryaltris. Package insert. Glenmark Specialty SA; 2021. Accessed January 19, 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211746s000lbl.pdf

This article originally appeared on MPR

Source Link


This blog is for information purposes only. The content is not intended as medical advice, diagnosis, or treatment. Should you have a medical or dermatological problem, please consult with your physician. None of the information or recommendations on this website should be interpreted as medical advice.

All product reviews, recommendations, and references are based on the author’s personal experience and impressions using the products. All views and opinions are the author’s own.

This blog post may contain affiliate links. An affiliate link means we may earn a commission if you click on a link and make a purchase, without any extra cost to you.

Please see our Disclaimer for more information.


The leading source for trustworthy and timely health and medical news and information. Providing credible health information, supportive community, and educational services by blending award-winning expertise in content, community services, expert commentary, and medical review. Everything about health is here with the difference of Dr.About

Related Articles

Leave a Reply

Back to top button